share_log

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

XORTX治療公司獲得在多倫多證券交易所創業板上市的最終批准
GlobeNewswire ·  2021/11/03 06:13

CALGARY, Alberta, Nov. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has received final approval from the TSX Venture Exchange (the "TSXV") to list its common shares on the TSXV effective as of the open of market on November 4, 2021 under the share symbol XRTX.  

加拿大阿爾伯塔省卡爾加里,2021年11月2日(Global Newswire)--XORTX治療公司(“XORTX Treateutics Inc.XORTX“或”公司)(CSE:XRX|NASDAQ:XRTX),一家專注於開發治療進行性腎臟疾病的創新療法的藥物療法公司,高興地宣佈,它已獲得多倫多證券交易所創業板(The TSX Venture Exchange)的最終批准。TSXV“)自2021年11月4日開市之日起,其普通股在多倫多證券交易所掛牌上市,股票代碼為XRTX。

Dr. Allen Davidoff, XORTX's President and CEO stated, "Listing on the TSXV is another significant milestone for the Company. This listing will further increase the Company's visibility and access to domestic and institutional investors."

XORTX總裁兼首席執行官艾倫·戴維多夫博士表示:“在多倫多證券交易所上市是本公司的又一個重要里程碑。此次上市將進一步提高本公司的知名度,並使其能夠接觸到國內和機構投資者。”

In connection with the listing of the common shares on the TSXV, the Company has submitted a request to voluntarily delist its common shares from the Canadian Securities Exchange (the "CSE"). Such delisting is expected to be effective on or shortly after the date the common shares commence trading on the TSXV.

關於普通股在多倫多證券交易所(TSXV)的上市,本公司已提交申請,自願將其普通股從加拿大證券交易所(the Canada Securities Exchange,簡稱“加拿大證券交易所”)退市。CSE“)。預計退市將於普通股在多倫多證券交易所開始交易之日或之後不久生效。

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSXV listing, as there will be no change in the trading symbol or CUSIP for the common shares.

由於普通股的交易編號或CUSIP不會改變,因此股東毋須交換其股票或採取任何其他與TSXV上市有關的行動。

About XORTX Therapeutics Inc.

關於XORTX治療公司

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.

XORTX治療公司是一家制藥公司,擁有兩種臨牀上正在開發的先進產品--用於常染色體顯性多囊腎病的XRX-008,用於與冠狀病毒/新冠肺炎感染相關的急性腎損傷的XRX-101,以及用於2型糖尿病腎病(T2DN)的臨牀前計劃。XORTX正在努力推進其臨牀開發階段的產品,這些產品針對異常的嘌呤代謝和黃嘌呤氧化酶,以減少或抑制尿酸的產生。在XORTX治療公司,我們致力於開發藥物來改善患者的生活質量和未來的健康。有關XORTX治療公司的更多信息,請訪問www.xortx.com。

For further information, please contact:

如需更多信息,請聯繫:

Allen Davidoff, CEO
adavidoff@xortx.com or +1 403 455 7727
         Nick Rigopulos, Director of Communications
nick@alpineequityadv.com or +1 617 901 0785
Dr. David Sans, Head of Corporate Development in New York City
dsans123@xortx.com or +1 347 573 0541
   
首席執行官艾倫·戴維杜夫(Allen Davidoff)
電子郵件:adavidoff@xortx.com或+1 403 455 7727
尼克·裏格普洛斯,通信總監
電子郵件:Nick@alpineequityAdv.com或+1 617 901 0785
大衞·桑斯(David Sans)博士,紐約市企業發展負責人
電子郵件:dsans123@xortx.com或+1 347 5730541

The CSE and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CSE和Nasdaq既沒有批准也沒有反對本新聞稿的內容。任何證券交易所、證券委員會或其他監管機構均未批准或不批准本報告所載信息。

Forward Looking Statements

前瞻性陳述

This press release contains express or implied forward-looking statements pursuant to Canadian and United Stated securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including statements about the Company's common shares being listed on the TSXV and delisted from the CSE. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is included in the Company's Management Discussion and Analysis for the year ended December 31, 2020 and the second quarter ended June 30, 2021, which are available at www.sedar.com and also under the heading "Risk Factors" in XORTX's Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.

本新聞稿包含根據加拿大和美國證券法作出的明示或暗示的前瞻性陳述。這些前瞻性表述及其影響僅基於XORTX管理層目前的預期,受許多因素和不確定因素的影響,這些因素和不確定性可能導致實際結果與前瞻性表述中描述的大不相同,包括有關本公司普通股在多倫多證券交易所上市並從CSE退市的表述。除非法律另有要求,否則XORTX沒有義務公開發布對這些前瞻性陳述的任何修訂,以反映本前瞻性陳述之後發生的事件或情況,或反映意外事件的發生。有關影響騰訊控股的風險和不確定因素的更詳細信息,請參見公司截至2020年12月31日的年度和截至2021年6月30日的第二季度的“管理層討論與分析”,這些報告可在www.sedar.com上查閲,也可在騰訊提交給美國證券交易委員會的F-1表格註冊聲明(可在美國證券交易委員會網站www.sec.gov上查閲)中的“風險因素”標題下查閲。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論